Alar Reports Positive Phase 1 Ketamine Therapy Results
06 Apr 2026 //
PR NEWSWIRE
Alar Announces ALA-1000`s Efficacy, Safety in Canine OA Study
16 Mar 2026 //
PR NEWSWIRE
Alar Pharmaceuticals Begins Study of ALA-3000 for TRD Depression
14 May 2025 //
PR NEWSWIRE
Alar Announces Developing Long-acting Buprenorphine Injectable ALA-1000
12 Jan 2022 //
PRNEWSWIRE

Market Place
Sourcing Support